吉利母企旗下基金入股以色列雷達晶片商Vayyar
吉利汽車(00175.HK)母企江吉利控股集團投資的GLy New Mobility Fund宣布,已完成對以色列4D雷達晶片方案供應商Vayyar Imaging的投資,本輪融資涉及1.08億美元,由Koch Disruptive Technologies (KDT)領投,其他投資者還包括Atreides Management及Battery Ventures等。
完成後,Vayyar估值超過10億美元,躋身獨角獸之列,並考慮於兩至三年內,在以色列以外地區進行首次公開招股(IPO)。
Vayyar研發的雷達晶片,可在不侵犯私隱下,看穿牆身和物件、實時動作跟縱,其技術現用於汽車及智能家居等領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.